You are here: Industry Insights > Bioverativ

News List

Bioverativ executive Rogerio Vivaldi to helm cell therapy producer Sigilon fiercebiotech
August 15, 2018
Sigilon Therapeutics is bringing on Bioverativ’s chief global therapeutic operations officer, Rogerio Vivaldi, M.D., to serve as its CEO.
Sanofi Quarterly Sales Sluggish with Focus on Integrating Bioverativ and Ablynx biospace
April 28, 2018
Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros.
Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia biospace
April 18, 2018
Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, joins the global hemophilia community in recognizing World Hemophilia Day 2018.
Sanofi confirmed the deal to buy Bioverativ for $11.6 B biospectrumasia
January 24, 2018
The French healthcare company intends to boost its earnings and strengthen its presence in the field of treatments for rare diseases.
Bioverativ and Bicycle Therapeutics to develop new haemophilia and sickle cell disease treatments pharmaceufical-technology
September 11, 2017
US biotechnology company Bioverativ has entered a new research collaboration with UK-based Bicycle Therapeutics to discover, develop and commercialise new therapies for haemophilia and sickle cell disease.
Bioverativ and Bicycle Therapeutics team up in haemophilia pharmatimes
September 07, 2017
Bioverativ and Bicycle Therapeutics have announced a research collaboration focused on the discovery, development and commercialisation of innovative therapies for haemophilia and sickle cell disease.
Bioverativ taps patient social network for input on hemophilia trial design fiercepharma
August 25, 2017
Bioverativ designed a hemophilia drug trial to address newly unearthed unmet needs, by gauging pain in addition to bleeding.